Use of polydeoxyribonucleotides in diabetic neuropathies
Number of patents in Portfolio can not be more than 2000
United States of America Patent
Stats
-
Oct 14, 1997
Grant Date -
N/A
app pub date -
Jul 21, 1995
filing date -
Aug 3, 1994
priority date (Note) -
In Force
status (Latency Note)
Importance
Abstract
A pharmaceutical composition comprising a polydeoxyribonucleotide of random sequence formula is disclosed, and P.sub.v, (dAp).sub.w, (dGp).sub.x, (dTp).sub.y, (dCp).sub.z wherein P.sub.v is 1-5 phosphoric radicals, (dAp).sub.w is 12-24 deoxyadenylic monomers, (dGp).sub.x is 10-20 deoxyguanylic monomers, (dTp).sub.y is 13-26 deoxythymidylic monomers, and (dCp).sub.z is 10-20 deoxycytidylic monomers; wherein the polydeoxyribonucleotide has: a homogenous anodic mobility in electrophoresis, an extinction coefficient E.sup.1%.sub.1 cm at 260.+-.1 nm=220.+-.10, an extinction coefficient E.sub.230 /E.sub.260 =0.45.+-.0.04, a molar extinction coefficient (referred to phosphorous), .epsilon.(P)=7750.+-.500, a rotary power ?.alpha.!.sup.20.degree..sub.D =53.degree..+-.6, and a reversible hyperchromicity as percent in native DNA h=15.+-.5, in combination with a pharmaceutically acceptable carrier or diluent. A method of treating or preventing a diabetic neuropathy using the polydeoxyribonucleotide is also shown.
First Claim
Family
International Classification(s)
- [Classification Symbol]
- [Patents Count]
Cited Art Landscape
Patent Citation Ranking
Recipient Email Address
Recipient Email Address
Comment
Recipient Email Address
Add to Portfolio(s)
To add this patent to one, or more, of your portfolios, simply click the add button.
This Patent is in these Portfolios:
Add to additional portfolios:
Last Refreshed On:
Changes done successfully